Arrowhead Pharmaceuticals

Kidneys brightly lit
Biotech

Arrowhead shares ‘select’ data for RNAi asset in kidney trial

Arrowhead said its RNAi asset was generally well tolerated among 14 patients with IgA nephropathy, also known as Berger’s disease.
Gabrielle Masson Mar 10, 2025 11:55am
graphic image of different colored hands shaking

Sarepta, Arrowhead ink $1B-plus deal for seven programs

Nov 26, 2024 11:18am
photo of a royal flush laid out on the poker table with chips scattered nearby

Arrowhead posts phase 3 data ahead of market clash with Ionis

Sep 3, 2024 9:27am
pond lilly pads

Arrowhead dips toes into obesity pond with 2 preclinical assets

Aug 14, 2024 3:50pm
Directions

Arrowhead axes one heart disease drug, goes all in on another

Jun 26, 2024 7:00am
fence palisade wall defense fence gate fortress fort

Arrowhead RNAi med lowers triglycerides in phase 3

Jun 3, 2024 9:54am